Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Stock Information for Scopus BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Scopus BioPharma Inc.

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.